PeterLGreenbergMD
Hematology • Palo Alto, CAHematologic Oncology
Professor Emeritus, Medicine - Hematology, Stanford University Medical Center
Dr. Greenberg is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Connect with other colleagues in the same hospital or clinic
- Search all U.S. specialist profiles and refer a patient
- Read the latest clinical news and earn CME/CEU credits
Office
300 Pasteur Dr
Palo Alto, CA 94305Phone+1 650-498-6000Fax+1 650-724-5203- Is this information wrong?
Education & Training
Stanford Health Care-Sponsored Stanford UniversityFellowship, Hematology, 1970 - 1971- Stanford Health Care-Sponsored Stanford UniversityResidency, Internal Medicine, 1967 - 1970
Washington University/B-JH/SLCH ConsortiumResidency, Internal Medicine, 1963 - 1965
George Washington University School of Medicine and Health SciencesClass of 1963
Certifications & Licensure
CA State Medical License 1968 - 2025- American Board of Internal Medicine Internal Medicine
- American Board of Internal Medicine Hematology
Awards, Honors, & Recognition
- CMS Meaningful Use Stage 1 Certification EpicCare Ambulatory EMR, Epic Systems Corporation, 2011
Clinical Trials
- Tipifarnib in Treating Patients With Myeloproliferative Disorders Start of enrollment: 2000 Jun 01
- Bevacizumab in Treating Patients With Myelodysplastic Syndrome Start of enrollment: 2001 Aug 01
- A Study of Darbepoetin Alfa in Patients With Myelodysplastic Syndrome (MDS) Start of enrollment: 2002 Feb 01
- Join now to see all
Publications & Presentations
PubMed
- p53 immunohistochemistry as an ancillary tool for rapid assessment of residual disease in TP53-mutated acute myeloid leukemia and myelodysplastic syndromes.Eula Fung, Nivaz Brar, Lauren Lawrence, James L Zehnder, Peter L Greenberg, Gabriel N Mannis, Tian Y Zhang, Dita Gratzinger, Jean Oak, Oscar Silva, Jason Kurzer, Brent...> ;American Journal of Clinical Pathology. 2024 Apr 20
- Shared and distinct mechanisms of UBA1 inactivation across different diseases.Collins, J., Magaziner, S., English, M., Hassan, B., Chen, X., Balanda, N., Anderson, M., Lam, A., Fernandez-Pol, S., Kwong, B., Greenberg, P., Terrier, B., Likhite, M...> ;The EMBO Journal. 2024 Feb 15
- How I reduce and treat posttransplant relapse of MDS.Alain Mina, Peter L Greenberg, H Joachim Deeg> ;Blood. 2024 Apr 4
- Join now to see all
Journal Articles
- Revised International Prognostic Scoring System (IPSS-R) for Myelodysplastic SyndromesGreenberg PL, Tuechler H, Schanz J, Sanz G, Garcia-Manero G, Sole F, Bennett JM, Bowen D, Fenaux P, Dreyfus F, Kantarjian H, Kuendgen A, Levis A, Malcovati L, Cazzola..., Blood, 9/2013
Abstracts/Posters
- Results of a Clinical Trial of H3B-8800, a Splicing Modulator, in Patients with Myelodysplastic Syndromes (MDS), Acute Myeloid Leukemia (AML) or Chronic Myelomonocytic...Peter L Greenberg, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
- A Feasibility Study of Biologically Focused Therapy for Myelodysplastic Syndrome Patients Refractory to Hypomethylating AgentsPeter L Greenberg, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
Press Mentions
Stanford Study Finds That Notable’s Drug Sensitivity Screening Platform Can Identify Potentially Useful Drugs for MDS Patients Refractory to Standard TherapiesJune 23rd, 2020
In Personalized Medicine Feasibility Study, Stanford Medical Center, with Partners Notable and Tempus, Able to Make Rapid Personalized Treatment Recommendations for 100 Percent of Blood Cancer PatientsApril 15th, 2019
Grant Support
- Clinical Trial: Subjects With (MDS) Receiving Hypomethylatin AgentsNational Center For Research Resources2008
- Monoclonal Antibody Therapy For Myelodysplastic SyndromeNational Center For Research Resources2005
- Safety And Efficacy Trial Of Bevacizuman: Anti-Vegf MABNational Center For Research Resources2004
- A Phase I Study Of Zarnestra And Gleevec In PatientsNational Center For Research Resources2004
- Mitoxantrone, Etoposide, Cytarabine, PSC 833 In AMLNational Center For Research Resources2000–2001
- Phase I Clinical Trial Of Vincristine, Adriamycin And Others In Relapse MyelomaNational Center For Research Resources1997–1999
- Cellular And Humoral Modulation Of HemopoiesisNational Cancer Institute1988–1990
- Cellular Modulation Of HemopoiesisNational Cancer Institute1985–1989
Professional Memberships
- Member
Hospital Affiliations
Stanford Health CarePalo Alto, California
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence:
